Welcome to our dedicated page for NanoString Technologies news (Ticker: NSTG), a resource for investors and traders seeking the latest updates and insights on NanoString Technologies stock.
NanoString Technologies, Inc. (NASDAQ: NSTG) is a renowned provider of life science tools for translational research and molecular diagnostics. Established in 2008, NanoString's technology is pivotal in enabling a diverse array of basic research, translational medicine, and in vitro diagnostics applications. The company's flagship product, the nCounter® Analysis System, is celebrated for its ability to profile the expression of hundreds of genes, miRNAs, or copy number variations simultaneously with high sensitivity and precision. This system has been referenced in over 300 peer-reviewed publications, underscoring its widespread adoption and scientific credibility.
The nCounter® system's versatility extends to diagnostic use as the nCounter Dx Analysis System, further solidifying NanoString's footprint in the molecular diagnostics landscape. The technology stands out for its cost-effectiveness and efficiency, making it a valuable tool for applications such as biomarker discovery and validation, as well as other translational research endeavors.
Among recent developments, NanoString Technologies has been embroiled in significant litigation with 10x Genomics, Inc. Notably, the European Unified Patent Court (UPC) declined to issue a second preliminary injunction against NanoString, allowing the company to continue its operations in specific jurisdictions. However, injunctions from the Regional Court Munich I and the UPC still impose restrictions on the sale and service of NanoString's CosMx Spatial Molecular Imager (SMI) instruments and reagents for RNA detection in Europe.
The legal battles extend to the United States, where 10x Genomics has filed multiple suits against NanoString alleging patent infringement related to the GeoMx Digital Spatial Profiler and the CosMx SMI. Recently, a jury in the U.S. District Court for the District of Delaware awarded 10x Genomics over $31 million in damages, asserting that NanoString's GeoMx products willfully infringed on several patents.
Despite these legal challenges, NanoString continues to thrive as a leader in its field, providing essential tools that drive significant discoveries in oncology, immunology, neuroscience, and beyond. The company's commitment to advancing human health through molecular diagnostics and translational research tools remains unwavering.
NanoString Technologies (NASDAQ:NSTG) reported preliminary product and service revenue of approximately $31 million for Q1 2022, missing previous guidance of $34 million to $38 million. This includes $10 million from GeoMx, with instrument revenue down by 31%, but consumables increased by 78%. nCounter revenue totaled $21 million, with a 11% decline in instrument sales. The company attributes the revenue shortfall to uneven sales execution and the realignment of its commercial team, but remains optimistic about long-term demand for spatial biology products.
NanoString Technologies (NASDAQ: NSTG) highlighted over 125 studies at the 2022 AACR meeting showcasing the adoption of its platforms in cancer research. With over 110 posters and 15 oral presentations, this marks a record for the company. Key studies utilized the GeoMx Digital Spatial Profiler and CosMx Spatial Molecular Imager, focusing on spatial biology and gene expression. The research includes innovative approaches such as high-plex protein imaging and multi-omic analyses, illustrating the growing importance of spatial profiling in developing cancer therapeutics.
NanoString Technologies (NASDAQ: NSTG) has launched the nCounter® Pro Analysis System, enhancing its instrument platform with advanced cybersecurity features and minimal bioinformatics requirements. This system, validated for a 21 CFR Part 11 environment, streamlines gene expression profiling and offers cloud-based analytics through ROSALIND, significantly improving data management and analysis. With over 5,300 peer-reviewed publications since the nCounter's 2008 inception, this release aims to support biomanufacturing and translational research, showcasing NanoString's commitment to innovation.
NanoString Technologies reported financial results for Q4 and full-year 2021, with Q4 product and service revenue reaching $42 million, an 18% increase year-over-year. The GeoMx DSP revenue surged to $18 million, marking a 48% growth, while nCounter revenue grew modestly by 2% to $24 million. The company anticipates total revenue for 2022 to range from $170 to $180 million, reflecting an 18% to 25% increase compared to 2021. However, expected adjusted EBITDA losses are forecasted to be between $55 million and $65 million. Cash reserves stood at $348.9 million.
NanoString Technologies, Inc. (NASDAQ:NSTG) announced its participation in the 42nd Annual Cowen Health Care Conference, scheduled virtually from March 7-9, 2022. CEO Brad Gray will present on Tuesday, March 8, 2022, at 1:30 PM ET. Interested parties can access the live webcast from the investor section of the company’s website. A replay will be available one hour after the live presentation, archived for 60 days. NanoString Technologies specializes in life science tools for research, with products like the nCounter® Analysis System and GeoMx® Digital Spatial Profiler.
NanoString Technologies has announced the launch of its CosMx Spatial Molecular Imager (SMI), a spatial multi-omics platform allowing for advanced protein and RNA expression analysis at single-cell resolution. This unveiling will take place at the Spatial Genomics Summit on February 28, 2022. The CosMx SMI can analyze up to 1,000 RNA and 100 protein analytes from intact tissue samples, enhancing both discovery and translational research. The company also introduced a Spatial Pioneer Program for early access to this technology.
NanoString Technologies (NASDAQ: NSTG) has launched a fully automated GeoMx® RNA protocol, enhancing workflow efficiency in research through its collaboration with Leica Biosystems. The new protocol allows users to prepare up to 30 slides daily, improving throughput and reproducibility while reducing manual processes. By utilizing the GeoMx Digital Spatial Profiler, researchers can conduct high-plex RNA expression profiling from diverse tissue samples. This advancement decreases hands-on time to under one hour, facilitating multi-sample studies and generating more reliable data.
NanoString Technologies (NASDAQ:NSTG) announced its participation in the 11th Annual SVB Leerink Global Healthcare Conference, scheduled for February 16-18, 2022. Brad Gray, President and CEO, will present on February 17, 2022, at 5:00 PM ET. The live webcast can be accessed through the company's investor section at www.nanostring.com. A replay of the presentation will be available one hour post-event and archived for 60 days. NanoString is known for its innovative life science tools, including the nCounter® Analysis System and GeoMx® Digital Spatial Profiler.
NanoString Technologies (NASDAQ:NSTG) has announced it will release its fourth quarter and fiscal year 2021 operating results on March 1, 2022, after market close. A conference call will follow at 4:30 PM ET to discuss these results and provide a business update. Interested parties can register for the call and access a replay starting at 7:30 PM ET on the same day, available until March 10, 2022. NanoString specializes in life science tools, utilizing technologies like the nCounter Analysis System and GeoMx Digital Spatial Profiler, contributing to significant advancements in biological research.
NanoString Technologies (NASDAQ: NSTG) announced an equity inducement award to its new Chief Commercial Officer, John D. Gerace, as part of his employment terms. The award includes 62,829 restricted stock units (RSUs) that will vest over three years based on continued service. Notably, 100% of unvested RSUs would fully vest upon a change in control if his employment is terminated without cause. The award is granted outside of their current equity plan but follows the guidelines of their 2018 Inducement Equity Incentive Plan.
FAQ
What is the market cap of NanoString Technologies (NSTG)?
What is NanoString Technologies' primary business?
What is the nCounter® Analysis System?
What are some applications of NanoString's technology?
Has NanoString been involved in any legal issues recently?
What was the outcome of the recent lawsuit in the U.S. District Court for the District of Delaware?
What is the significance of the nCounter Dx Analysis System?
How many peer-reviewed publications have cited the nCounter® system?
What is the cost advantage of NanoString's technology?
What are the legal implications of the injunctions against NanoString in Europe?
How does NanoString contribute to advancements in human health?
